About Us
Monet Pharmaceutical’s mission is to transform the drug discovery process with our new, novel and elegant Protein Painting technology. Protein Painting facilitates a simpler, faster and more effective path to the discovery of new drug targets and novel therapies.
Protein Painting was co-invented by leading scientists Dr. Lance A. Liotta, MD, PhD, Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University and Dr. Alessandra Luchini, associate professor, Applied Proteomics and Molecular Medicine at George Mason University in 2013.
We’ve assembled a team of highly accomplished professionals with expertise in drug development and commercialization to help guide our mission to transform drug discovery.
Management Team
Lance Liotta, MD, Ph.D
Clinical Pathologist
Co-Inventor of Protein Painting
Since 2005, Dr. Liotta has served as Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology, NCI, Deputy Director of NIH, Co-Director of the NCI/FDA Clinical Proteomics Program, and Director of the Anatomic Pathology Residency Program. Over his career, Dr. Liotta has more than 100 issued or allowed patents and more than 690 publications, resulting in the invention of transformative technologies in the fields of diagnostics, cancer molecular therapeutics. These include microdissection technologies (Laser Capture Microdissection, prototype displayed in the Smithsonian collection), and proteomics technologies (Reverse Phase Protein Microarrays, Biomarker Harvesting Nanoparticles, preservation chemistries for molecular analysis, and “protein painting” for drug target mapping) that have been used to make broad discoveries in cancer biology.
Dr. Liotta is an ISI highly cited investigator and the recipient of the 2015 Outstanding Virginia Faculty Award (SCHEV), the Flemming Award for Cancer Research, the Warner-Lambert Parke Davis Award, and the Surgeon General’s Medallion. He is Board Certified in Anatomic Pathology and is Medical Director of the GMU CAP/CLIA certified clinical proteomics Lab.
Alessandra Luchini, Ph.D
Nanotechnology
Co-Inventor of Protein Painting
Alessandra Luchini is Associate Professor in the Center for Applied Proteomics and Molecular Medicine at George Mason University. Her research interests are focused on developing technologies that improve current diagnostics and therapeutics for devastating diseases including cancer, inflammatory and infectious diseases. Dr. Luchini has authored peer reviewed publications in scientific journals in chemistry, nanotechnology and proteomics and is co-inventor in a series of issued and licensed patents covering her Mason nanotechnology research.
In 2009, Dr. Luchini was awarded the Premio award for the top Italian scientist working in the US, Canada and Mexico and the Euwiin Gold Innovation in Science award. In 2011, Dr. Luchini was named as one of the top 10 most brilliant scientists by Popular Science. Dr. Luchini earned a degree in Chemical Engineering cum laude and a PhD in Bioengineering both at the University of Padova, Padova, Italy.
Amanda Haymond Still, Ph.D
Protein Biochemist
Protein Painting
Amanda Haymond Still is a Research Assistant Professor in the Center for Applied Proteomics and Molecular Medicine at George Mason University. Her research interests include development and optimization of drug candidates for diseases including cancer and bacterial infection. Dr. Haymond Still had authored peer-reviewed publications in scientific journals in chemistry, enzymology, and drug target identification.
Dr. Haymond Still earned a BS degree in Chemistry summa cum laude in 2013 and a PhD in Biochemistry in 2017 both at George Mason University.
Mikell Paige, Ph.D
Organic Chemist
Small Molecule Development
Need summary professional bio. I do not have this information. I can get it from Dr. Paige when I am back from vacation.
Nunc sapien quam, hendrerit non blandit sit amet, feugiat lacinia ex. Mauris interdum, turpis semper ultrices pulvinar, justo turpis sollicitudin leo, efficitur ultrices nunc eros sit amet eros. Mauris varius eu urna quis consectetur. Etiam eu cursus ligula. Nullam at nisi augue. Pellentesque eget nulla eros. Curabitur dapibus ac mi et volutpat. Nam vehicula dui vel cursus pretium. Phasellus aliquet gravida consequat. Vestibulum id posuere neque. Integer pellentesque arcu a malesuada pellentesque. Sed nisi dui, aliquam vitae tempus nec, finibus ut nibh.
Board of Directors
Walter Olesiak
Walter Olesiak has over 28 years experience in business development, healthcare consulting and venture investment. Walter spent 12 years in venture investments with Mitsui Ventures, during which time he held positions as a board member or observer in 10 portfolio companies. Prior to Mitsui Walter spent 6 years with Cambridge Pharma Consultancy (an IMS Health company) advising on global pharmaceutical pricing, reimbursement and market access issues to leading pharmaceutical and biotechnology companies. Walter also spent 8 years in Tokyo in various roles with Genzyme Japan and SRL, Inc. Walter holds a AB in Biochemical Sciences from Harvard University and MBA from Cornell University.
Cohava Gelber, Ph.D, MBA
Cohava Gelber, Ph.D., MBA has vast experience in various executive positions in biotech and pharmaceutical companies (ImmuLogic Pharmaceutical Corp., Molecular Discoveries, MannKind Corp., Serpin Pharma). As vice president of R&D at Mannkind Corp. (MNKD), she was responsible for nonclinical development and clinical immune safety of drugs from pre-IND through phase III clinical trials. She has secured over $500M of federal funding and authored over 70 patents or patent applications. Dr. Gelber received her Ph.D. from the Weizmann Institute and MBA from Cornell University, as well as post-doctorate training at Stanford University.
Guy Yachin, Eng., MBA
Guy Yachin is the CEO and President of Serpin Pharma, a Virginia based, clinical stage, immunotherapy company. He has served as CEO and active board members in multiple private and public companies, among them NasVax Ltd. (focused on improved immunotherapeutics), MGVS Ltd. (a cell therapy company), Chiasma Inc. (Nasdaq:CHMA) - oral delivery of macromolecule drugs, Orgenesis (Nasdaq:ORGS) - cell therapy, Enzymotec (Nasdaq:ENZY), specialty chemicals, and more. Mr. Yachin holds a BSc. in Industrial Engineering and Management and an MBA from the Technion - Israel Institute of Technology.